After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.
Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Background: Therapeutic options for patients with treatment-resistant schizophrenia are limited, and combination treatment with atypical antipsychotic drugs is an often used strategy. We tested ...
Psilocybin significantly reduces confidence in negative self-beliefs four weeks after administration, with effects linked to ...
Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 Per Share Related to ...
AbbVie Inc . (NYSE:ABBV) delivered strong financial results for Q4 2024, surpassing analysts' expectations with an earnings per share (EPS) of $2.16, compared to the forecast of $2.06. The company ...